Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD4 | P01730 | 10/20 | 0.60 |
| ▸ | PKM | P14618 | 4/20 | 0.52 |
| ▸ | HTT | P42858 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9216667 | 0.88 | CD4 (0.71) | CD4PKMHTTALDH1A1POLB | |
| SCHEMBL5557223 | 0.86 | CD4 (0.69) | CD4PKMHTTALDH1A1POLB | |
| SCHEMBL23217199 | 0.83 | PKM (0.74) | PKMHTTALDH1A1POLBLMNA | |
| SCHEMBL3110165 | 0.83 | PKM (0.54) | CD4PKMHTTALDH1A1POLB | |
| SCHEMBL26839792 | 0.83 | CD4 (0.57) | CD4PKMHTTALDH1A1POLB | |
| SCHEMBL12691713 | 0.83 | CD4 (0.64) | CD4PKMHTTALDH1A1POLB | |
| Bromide SCHEMBL1159786 | 0.82 | PKM (0.72) | PKMHTTALDH1A1POLBLMNA | |
| SCHEMBL18911325 | 0.82 | CD4 (0.63) | CD4PKMALDH1A1POLBSMN1; SMN2 | |
| SCHEMBL4109280 | 0.81 | CD4 (0.60) | CD4PKMHTTALDH1A1POLB | |
| SCHEMBL25010136 | 0.81 | CD4 (0.69) | CD4PKMHTTALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8420626-B2 | Arene connected polyamine macrocyclic derivatives, preparation methods and pharmaceutical uses thereof | BEIJING MOLECULE SCIENCE AND TECHNOLOGY CO., LTD. (CN) | 2013-04-16 | — | — | US | disclosed |
| US-20100179116-A1 | Arene Connected Polyamine Macrocyclic Derivatives, Preparation Methods and Pharmaceutical Uses Thereof | BEIJING MOLECULE SCIENCE AND TECHNOLOGY CO., LTD. (CN) | 2010-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179116-A1 | Arene Connected Polyamine Macrocyclic Derivatives, Preparation Methods and Pharmaceutical Uses Thereof | SRM, SP1, SMS | CD4 47/4885PKM 119/4885HTT 578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.